Challenges and Limitations of Personalized Medicine in the Treatment of Breast Cancer

Personalized medicine is a medical method Which uses genomic and molecular diagnostic methods to make care decisions in the treatment of diseases, including cancers. This study attempts to investigate the challenges and limitations of personalized medicine treatment in breast cancer, which is a high prevalence in women. Examining these challenges can be important in managing and improving the crisis so that if we use this technique in Iran as an executive, we will be aware of the opportunities and threats we face.Two common tests for breast cancer, BRCA1 Analysis and Oncotype DX have been used. The results of the tests can determine the risk of breast and ovarian cancers, improve the surgical consultation process, the risk of recurrence that helps in prognosis, and also the decision to chemotherapy .The three interviewed groups include physicians, reimbursers, and patient advocares. The results include two groups , timing and reimbursement. Doctors priorities are accelerated in the treatment process, and one of the challenges is the timing of the testing process because the results are delayed by the physician, which jeopardizes the health and survival of the patient. Also payers and patient advocates group, payouts and financial issues have been considered, and if these challenges are in the best interest of the patient, the same routine treatments can be used, otherwise the benefit of the patient will be prioritized.As a consequence poorly coordinated diagnostic testing are the current oncology reimbursement model are barriers to the use of Personalized medicine in cancer care.

Keywords:

genomic and molecular diagnostic , BRCA1 Analysis , Oncotype DX